FDA Approves Dupilumab for Allergic Fungal Rhinosinusitis in Adults and Children 6 Years and Older

Executive Brief

News Report

The News: FDA approves dupilumab for allergic fungal rhinosinusitis in patients aged 6 and older.
Clinical Win: This approval offers a targeted therapy option that may reduce the need for surgery and systemic corticosteroids.
Target Specialty: Otolaryngology

Key Data at a Glance

Trial Duration: 52 weeks
Participants Enrolled: 500
Primary Endpoint: Improvement in Lund-Mackay scores

The FDA has approved dupilumab (Dupixent) for the treatment of allergic fungal rhinosinusitis (AFRS) in adults and pediatric patients aged 6 years and older. This approval, announced on February 24, 2026, marks a significant advancement in the management of a condition that can lead to severe complications if untreated.

Clinical Context

Allergic fungal rhinosinusitis (AFRS) is a chronic inflammatory condition characterized by an allergic reaction to fungi in the sinuses, leading to thick mucus production and sinus obstruction. It affects up to 8% of patients with chronic sinusitis and nasal polyps, particularly in humid climates where fungi thrive. Symptoms can include nasal congestion, facial pain, and loss of smell, significantly affecting quality of life. If left untreated, AFRS can cause serious complications such as sinus expansion, erosion of surrounding bone, and even spread to the eyes or brain, which can lead to vision problems and facial deformities. Current treatment options often involve systemic corticosteroids and surgical interventions, but these can have significant side effects and may not always be effective. The approval of dupilumab provides a targeted therapy option that addresses the underlying inflammation associated with AFRS, potentially reducing the need for surgery and systemic corticosteroids.

Key Findings

The FDA approval of dupilumab (Dupixent) for allergic fungal rhinosinusitis is based on a 52-week study demonstrating significant improvements in sinus opacification, as measured by CT scan scores, compared to placebo [1].

The trial enrolled 500 participants aged 6 years and older with a history of sino-nasal surgery and confirmed diagnosis of AFRS [1].

Event rates showed a reduction in the need for systemic corticosteroids and sinus surgery, with dupilumab significantly improving nasal congestion and sense of smell [1].

The primary endpoint was the improvement in Lund-Mackay scores, indicating enhanced sinus opacification and reduced disease severity [1].

What This Means for Clinical Practice

Dupilumab is now an important therapeutic option for patients aged 6 years and older with allergic fungal rhinosinusitis, particularly for those who have undergone previous sinus surgery. The data supports its use in reducing the need for systemic corticosteroids and surgical interventions, which can be associated with significant adverse effects. Clinicians should consider this therapy for patients experiencing chronic symptoms of AFRS, especially those with a history of recurrent sinus surgeries. The introduction of dupilumab may change the management approach for AFRS, emphasizing a more targeted treatment strategy that can improve patient outcomes and quality of life. How this new indication will be integrated into existing treatment guidelines remains to be seen.

Clinical Perspective

Workflow: Clinicians can now prescribe dupilumab as a first-line treatment for patients with allergic fungal rhinosinusitis, potentially streamlining management protocols.

Economics: The use of dupilumab may reduce healthcare costs associated with recurrent surgeries and long-term corticosteroid use.

Patient Outcomes: Patients can expect improved quality of life with reduced symptoms and complications associated with allergic fungal rhinosinusitis.

Editorial Team, Otolaryngology

References

FDA — FDA approves drug for adult and pediatric patients aged 6 and older with allergic fungal rhinosinusitis

FDA Approves Dupilumab for Allergic Fungal Rhinosinusitis in Adults and Children 6 Years and Older

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

What This Means for Clinical Practice

Clinical Perspective

References

Get weekly drug updates for Otolaryngology in your inbox.

Related Drug Updates

FDA Approves Lunsotogene Parvec for Genetic Hearing Loss: A New Era for OTOF Mutation Patients

FDA Approves Lunsotogene Parvec-Cwha for OTOF-Related Hearing Loss: First Gene Therapy for Deafness

FDA Approves Dupilumab for Allergic Fungal Rhinosinusitis: Significant Improvement in Sinus Opacification

Verified HCP Portal